secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001104659-22-115937
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q3 revenue $735M, net loss $169M; narrows FY 2022 revenue guidance to ~$2.0B
--------------------------------------------------------------------------------

- Total revenue $735M (Q3 2021: $179M); net loss $169M vs $322M prior year.
- Cost of sales $435M includes $249M excess/obsolete inventory losses.
- Refines FY 2022 revenue guidance to ~$2.0B, low end of prior $2.0-2.3B range.
- Over 94M doses of COVID-19 vaccine delivered globally; booster authorized in U.S., EU, others.
- Cash and restricted cash $1.3B as of Sept 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/0001104659-22-115937-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465922115937/tm2230063d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115937

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer